

Reference: FOI.ICB-2324/071

Subject: Liver Disease Pathways in Primary Care

*I can confirm that the ICB **does hold some of the information requested**; please see responses below:*

QUESTION	RESPONSE
Please refer to requesters template enclosed.	

The information provided in this response is accurate as of 23 May 2023 and has been approved for release by Lisa Manson, Director of Performance and Delivery for NHS Bristol, North Somerset and South Gloucestershire ICB.

Q1. Name and position of person answering the survey

Head of Elective Care – Performance & Delivery Directorate

Q2. Please enter the name of your ICB

Bristol, North Somerset, South Gloucestershire (BNSSG)

Q3. Do you have a named person within the ICB who is responsible for liver disease?

Yes

No

If yes, please move to Q3a

If no, please move to Q3b

Q3a If yes, please provide the name, title and email address of this person

Name:

Title:

Email address:

Q3b In the absence of a named contact for liver disease, please provide the name, title and email address of the person who should be contacted regarding liver health

Name: Lisa Manson / Head of Elective Care

Title: Director of Performance & Delivery / Head of Elective Care

Email address: enquiries should be sent to bnssg.plannedcareperformance@nhs.net

Q4. Do you have a commissioned pathway for a) the interpretation of abnormal liver blood tests? b) responding to liver disease more generally? Please could you attach/hyperlink any pathway documents to your response.

Yes, pathways for both

Yes, pathway for abnormal liver blood tests

Yes, pathway for responding to liver disease more generally

No pathways for either (the ICB commissions these pathways as part of the Acute contracts, but we do not commission specific pathways)

If answer to any of these is yes, please move to Q5

If answer is no pathways for either, please move to Q8

Q5. Is/Are the pathway(s) rolled out across the entire ICB or CCG locality specific?

Yes, across the entire ICB

No, locality specific

Q6. Does it include an endorsed pathway for the management of abnormal liver blood tests that follows the BSG guidance?

- Yes
- No
- Not applicable

Q7. Is liver fibrosis assessment part of your pathway?

- Yes
- No
- Not applicable

If yes, please move to Q7a

If no, please move to Q8

Q7a. Please indicate how fibrosis is assessed (Please tick all that apply):

- Fibroscan
- ELF Test
- FIB-4
- NAFLD fibrosis score
- iLFTs
- Other:

Q8. Do you have an additional pathway that proactively case-finds individuals who may be at high-risk of liver disease?

- Yes
- No

If yes, please move to Q9

If no, please move to Q11

Q9. How does your pathway define individuals as high risk of liver disease? (Please tick all that apply)

- Diabetes
- Alcohol risk
- Obesity
- Obesity with other metabolic risk factors
- Risk factors for viral hepatitis
- Other:

Q10. How are these individuals identified? (Please tick all that apply)

- At annual chronic disease or year of care review

- During the NHS Health Check
- Opportunistically during consultations
- Using IT system prompts or pop-ups
- Other:

Q11: Does your contract with Drug and Alcohol Recovery Service providers include providing a liver disease diagnostic test?

- Yes
- No

The ICB does not directly commission the Drug and Alcohol Recovery Service, however we work in partnership with the Local Authorities and the voluntary, community and social enterprise (VCSE) sector.

Bristol City Council - <https://www.bristol.gov.uk/data-protection-foi/freedom-of-information-foi>

North Somerset Council - <https://www.n-somerset.gov.uk/council-democracy/data-protection-freedom-information/freedom-information/about-freedom-information-foi>

South Gloucestershire Council - <https://www.southglos.gov.uk/council-and-democracy/data-protection-and-freedom-of-information/making-a-freedom-of-information-request/>

Q12: Does your contract with Weight Management Service providers include providing a liver disease diagnostic test?

- Yes
- No - Tier 2 weight management services are commissioned by Public Health/Local authorities.

Q13. Does the ICB monitor the breadth of adoption and efficacy of liver disease pathways in primary care in your area?

- Yes
- No

If yes, please move to Q14
If no, please move to Q15

Q14. Where are these statistics published?

Q15. Are you aware of current statistics relating to liver disease in your area and do you monitor these?

- Yes (aware)
- No (not monitored in/by the team)

Q16. Which Community Diagnostic Centre(s) serve your ICB?

None currently

Q17. Is/Are your local Community Diagnostic Centre(s) used for liver disease diagnostics?

Yes

No

Not applicable at this stage – see response to Q16

Q18. Would you be willing to share your pathway information with other ICBs for best practice purposes?

Yes

No

Not applicable